UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC  20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of report (Date of earliest event reported):  July 10, 2014

Immune Pharmaceuticals Inc.
(Exact Name of Registrant as Specified in Charter)

N/A
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

On July 10, 2014, Dr. Isaac Kobrin resigned from his position as a member of the board of directors of Immune Pharmaceuticals Inc. (the “Company”), effective immediately. Dr. Kobrin also resigned from his position as the chairperson of the Research and Development Committee. His resignation was not due to any disagreement with the Company.

On July 10, 2014, Mr. Cameron Durrant accepted the Company's offer to be appointed as a member of the board of directors, effective July 10, 2014. The Company’s board of directors approved the appointment of Mr. Durrant as an independent director to fill the vacancy created by the resignation of Mr. Kobrin from the board of directors of the Company and to hold office as a Class II director until the 2015 annual meeting of stockholders and until his successor is duly elected and qualified or until his earlier death, resignation or removal. Mr. Durrant will serve on the Compensation Committee and Research and Development Committee of the board of directors of the Company.

Mr. Durrant will be entitled to receive the same compensation as the other non-employee directors of the Company are entitled to receive, as approved by the Company's board of directors on October 10, 2013. Mr. Durrant’s compensation shall be prorated at $8,888 from July 10, 2014 until September 30, 2014. In addition, Mr. Durrant shall receive options to purchase 50,000 shares of common stock of the Company, to vest quarterly over a three (3) year term commencing three (3) months from the effective date of his appointment.

There are no arrangements or understandings between Mr. Durrant and any other person pursuant to which he was selected as a director. The Company is not aware of any transaction in which Mr. Durrant has an interest requiring disclosure under Item 404(a) of Regulation S-K. 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.